BANGKOK - Docquity, Southeast Asia’s largest community of healthcare professionals (HCPs), and global biopharmaceutical leader AstraZeneca developed ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of respiratory syncytial virus ... possible vaccine-associated enhanced ...

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.

Global analytics software leader, FICO, will announce its second quarter fiscal 2025 results on April 29, 2025, after the market closes and will host a conference call on April 29th at 5:00 p.m.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of ...

Leveraging structural biology-based design, we engineered the RSV pre-F protein and validated the potential of IIC self-splicing introns as a vaccine platform for preventing infectious diseases ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory ...